Brief: GT Biopharma Announces Executive Leadership Transition To Implement Next Phase Of Strategic Journey

GT Biopharma

08/11/2021 12:52

Nov 8 (Reuters) - GT Biopharma Inc  GTBP.O :
    * GT BIOPHARMA ANNOUNCES EXECUTIVE LEADERSHIP TRANSITION TO
IMPLEMENT NEXT PHASE OF STRATEGIC JOURNEY
    * GT BIOPHARMA INC - APPOINTS GREGORY BERK, CURRENT
PRESIDENT OF
RESEARCH AND DEVELOPMENT AND CHIEF MEDICAL OFFICER, AS INTERIM
CHIEF EXECUTIVE OFFICER
    * GT BIOPHARMA INC - NAMES MICHAEL BREEN, CURRENT BOARD
MEMBER, AS
EXECUTIVE CHAIRMAN OF BOARD
    * GT BIOPHARMA INC - APPOINTS GAVIN CHOY, CURRENT CHIEF
CLINICAL
DEVELOPMENT OFFICER, AS ACTING CHIEF FINANCIAL OFFICER
    * GT BIOPHARMA INC - BOARD HAS INITIATED SEARCH PROCESS TO
IDENTIFY INDIVIDUALS FOR PERMANENT POSITIONS FOR BOTH CEO AND
CFO ROLES
    * GT BIOPHARMA INC - ANTHONY CATALDO, CHAIRMAN & CHIEF
EXECUTIVE
OFFICER AND MICHAEL HANDELMAN, CHIEF FINANCIAL OFFICER WILL BOTH
PURSUE OTHER INTERESTS

Source text for Eikon:  ID:nPn4w1Bf8a 
Further company coverage:  GTBP.O 

 ((Reuters.Briefs@thomsonreuters.com;;))